CD38 and Miyoshi myopathy: Therefore, targeting CD38+ cells, i.e., plasma cells and non-plasma cells responsible for immunosuppression (e.g., proliferating Tregs) with daratumumab (DARA), an anti-CD38 monoclonal human IgG1 kappa antibody, may be an effective strategy in the treatment of MM patients [19].